Alector, Inc.
- Jurisdiction
United States - LEI
549300Z8RQOIY1JMHC25 - ISIN
US0144421072 (ALEC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€69.20M - Gross margin
93.5% - EBIT
-€114.74M - EBIT margin
-165.8% - Net income
-€98.34M - Net margin
-142.1%
Statement period: - (published )
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Berkley Neil Lindsay | Principal Financial Officer |
|
|
|
|
| Kenkare-Mitra Sara | President and Head of R&D |
|
|
|
|
| Rosenthal Arnon | Chief Executive Officer |
|
|
|
|
| Wong-Sarad Grace | Principal Accounting Officer |
|
|
|
|
| Hammond Paula | N/A |
|
|
|
|
Earnings Calls
Latest earnings call: February 27, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |